viewImugene Ltd

Imugene CEO Leslie Chong backs immuno-oncology strategy with further share purchase

The company's lead product is HER-Vaxx, a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer.

Imugene Ltd - Imugene CEO Leslie Chong backs immuno-oncology strategy with further share purchase
Chong now holds more than 4 million shares

Imugene Ltd (ASX:IMU) managing director and chief executive officer Leslie Chong has further demonstrated confidence in the company’s immuno-oncology strategy by purchasing more shares.

Chong purchased 475,240 at 1.8 cents per share on March 16 and now holds 4,387,124 shares and 77,098,765 options.

PD1-Vaxx study

The company’s PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer.

The drug will be trialled in patients with non-small cell lung cancer (NSCLC), the most common type of lung cancer accounting for around 80% of cases.

The study is planned to begin in 2020 and will be conducted at up to 6-10 sites in North America and Australia under a U.S. Food & Drug Administration (FDA) Investigational New Drug (IND) application.

HER-Vaxx trial

The HER-Vaxx trial is targeting HER-2 positive gastric cancer.

To date, the Phase 1b stage of the study has tested three different doses of the HER-Vaxx vaccine in combination with chemotherapy.

All key endpoints were met to identify the optimal dose of HER-Vaxx.

Imugene continues to monitor the enrolment, data collection and the patient’s immune responses to the vaccine.

Quick facts: Imugene Ltd

Price: 0.034 AUD

Market: ASX
Market Cap: $150.48 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...



Imugene obtains FDA guidance for KEY-Vaxx immunotherapy clinical development...

Imugene Ltd (ASX:IMU) managing director & CEO Leslie Chong updates Proactive Investors on the clinical-stage immuno-oncology company’s development of its KEY-Vaxx cancer vaccine.   The company had a pre-investigational new drug meeting with the US Food and Drug Administration...

on 19/3/19

2 min read